2017 American Transplant Congress
Results of the Initial Phase of the Portable Organ Care System (OCS™) Liver PROTECT Pivotal Trial.
PurposeThe OCS Liver PROTECT Trial is a prospective, international, randomized controlled trial to evaluate the impact of using portable ex-vivo warm, oxygenated blood perfusion using…2017 American Transplant Congress
The TAKE-IT Intervention Improves Medication Adherence in Adolescent Kidney Transplant Recipients.
Poor adherence to immunosuppressive medications limits renal allograft survival. This randomized controlled trial, evaluated whether young kidney transplant recipients administered a behavioral intervention showed greater…2017 American Transplant Congress
Donor-Derived Cell-Free DNA Correlates with Antibody-Mediated Rejection in Kidney Allografts.
Purpose: Donor-derived cell-free DNA (dd-cfDNA) is a noninvasive test of allograft injury that may enable more frequent, quantitative, and safer assessment of allograft rejection and…2017 American Transplant Congress
U.S. Outcomes in Early Liver Transplantation for Alcoholic Hepatitis: Results from the American Consortium of Early Liver Transplantation for Alcoholic Hepatitis (ACCELERATE-AH).
INTRODUCTIONA Franco-Belgian protocol showed that early liver transplant (LT) in severe alcoholic hepatitis (AH) could improve survival with low incidence of alcohol relapse (AR). Application…2017 American Transplant Congress
Tissue Transcriptional Profile of Portal Inflammation with Interface Activity in Pediatric Liver Transplant (LT) Recipients with Normal Liver Tests Closely Resembles T Cell Mediated Rejection (TCMR).
Background: Significant inflammation±fibrosis is frequently seen in biopsies (bxs) of pediatric LT recipients with normal liver tests assessed for immunosuppression withdrawal. The pathogenesis of these…2017 American Transplant Congress
Donor-Derived Cell-Free DNA Is a Dynamic Biomarker of Active Rejection in Kidney Allografts.
Purpose: Donor-derived cell-free DNA (dd-cfDNA) has shown promise as a biomarker in identification of allograft rejection. Here we report on the changes in dd-cfDNA prior…2017 American Transplant Congress
Donor-Derived Cell-Free DNA Normal Range and Biological Variation Defined in a Reference Population.
Purpose: Donor-derived cell-free DNA (dd-cfDNA) in the circulating blood of transplant recipients has shown promise as a non-invasive biomarker of acute rejection. This analysis was…2017 American Transplant Congress
Variability in Tacrolimus Concentrations Across Pediatric Solid Organ Transplants.
PURPOSE: We characterized the evolution of out-of-range tacrolimus (TAC) concentrations and associated factors during 1 year following a pediatric solid organ transplant (SOT).METHODS: Heart, kidney…2017 American Transplant Congress
Perceived Patient Barriers for Kidney Transplant Evalution Among Transplant Center Staff.
Background: The Southeastern United States has the lowest rates of kidney transplant in the nation. Disparities in transplant access among end stage renal disease (ESRD)…2017 American Transplant Congress
Hispanic Paradox in Patients with Liver Cirrhosis.
Northwestern University Transplant Research Collaborative, Chicago
IntroductionA paradoxical survival advantage for Hispanics compared to non-Hispanic whites (NHW) has been well described for many clinical conditions e.g diabetes however, with respect to…
- « Previous Page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- 13
- Next Page »